Sindh Pharma: A Board That Cannot Challenge Itself

1. Board independence is illusory. The lawyer depends on the founder for fees and the 14-year director cannot be presumed independent. With three family members, the board cannot form an independent majority on any contested matter. Why it matters: the board's only real function is to challenge executive power; a board that cannot say no is a rubber stamp.
2. Audit committee compromised. Its chair earns PKR 6m from the company he is meant to oversee, and internal audit reports to the CFO - the very person whose numbers are audited. Why it matters: the assurance line is structurally captured, so control failures reach the board only if management permits.
3. Related-party transaction at above-market rent. A 30% premium to a CEO-connected landlord transfers value from shareholders to the CEO's household. Why it matters: it is a direct expropriation of minority holders and a related-party transaction requiring independent approval and disclosure.
4. Whistleblower allegation and the instruction to 'handle it quietly'. Quality data alteration on export products is a product-safety and regulatory matter. Why it matters: suppressing it converts a control problem into a governance and legal one, and exposes directors personally.
5. Concentration of chair and founder roles, with family CEO. Why it matters: no separation of oversight from execution; succession and dissent are impossible.

Each failure is connected: captured assurance plus a compliant board plus a dominant family is the mechanism by which the related-party rent and the quality fraud can persist.

Board and committees

• Reconstitute the board so that at least half, excluding the chair, are genuinely independent: no fee relationship with the company or family, tenure under nine years, no family tie.
• Separate chair and CEO. If the family retains the chair, appoint a senior independent director with a mandate to convene meetings of independent directors.
• Rebuild the audit committee: entirely independent, chaired by someone with recent relevant financial experience, and no consultancy fees to any committee member. Terminate the cousin's consultancy or remove him from the committee - not both roles.
• Internal audit must report functionally to the audit committee, with unrestricted access and a private session without the CFO at every meeting.
• Establish a related-party transaction committee of independent directors with authority to obtain independent valuations.

Warehouse lease

1. Immediate disclosure to the board and, if listed rules require, to the market, with full terms.
2. Independent valuation and benchmarking against comparable rents.
3. If the premium is confirmed, renegotiate to market or terminate; recover the excess where legally possible.
4. Going forward, all related-party transactions above a threshold need prior independent approval, an abstention by the interested director, and annual disclosure.

Sequencing: protect the whistleblower and preserve evidence first; then fix the assurance line; then the board composition; then the lease. Reversing the order lets the evidence disappear while the board debates structure.

Immediate handling

• Do not follow the chairman's instruction to handle it quietly. A director who suppresses a product-safety allegation may breach duties of care, skill and diligence, and may face personal liability for resulting harm.
• Acknowledge the whistleblower in writing, confirm no retaliation, and protect identity.
• Preserve records: batch-release logs, audit trails, emails, and the QC system's access logs. Suspend any deletion or amendment rights for relevant staff.
• Escalate to the audit committee (properly constituted) and commission an independent investigation reporting to that committee, not to the CEO or chairman.
• If the allegation involves export specifications, consider a regulatory notification and, where product safety is affected, a product hold. Legal privilege should be used for the investigation, but not to conceal findings from the board.

Director exposure

• Duties of care and good faith, avoidance of conflicts, and the obligation not to permit misleading disclosure.
• The chair's instruction, if followed, would be a decision made for an improper purpose; board minutes should record dissent.
• Personal liability risk rises where a director knew of the issue and did nothing.

Disclosure

• Material quality failures affecting export compliance are likely to be material to shareholders; disclose in the annual report or as required by listing rules once facts are established.
• Coordinate with external auditors and, if necessary, legal counsel on regulatory reporting.
• Announce remedial actions alongside the disclosure - credible remediation protects reputation better than silence discovered later.

Minimum action for the incoming head of finance: put the instruction and your objection in writing to the chairman, and copy the senior independent director.